Search results
Buy Biocon; target of Rs 400: Sharekhan
CNBC Awaaz· 1 day agoSharekhan is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 400 in its research report dated June 28, 2024.
Falsified Ozempic reported from more countries: WHO says, on popular diabetes and weight loss drug
The Hindu· 2 days agoAt least 14 countries have reported the detection of falsified Ozempic, a World Health Organization representative said, as demand for the popular diabetes and weight loss ...
PLI scheme for obesity, diabetes drugs likely by 2026: Report
Business Today· 4 days agoIndian pharma companies such as Dr. Reddy's Laboratories, Lupin, Zydus Cadila, and Sun Pharma are...
Dengue in obese children is more likely to result in hospitalisation, study finds | Business Insider...
Business Insider India· 5 days agois currently in the grips of a major dengue surge, with over 1,000 cases reported within the first...
Ultra-processed foods ‘should carry tobacco-style warning’ – scientist
Just Food· 5 days agoIts report said 117,290 deaths a year are caused by diets high in processed meats and 252,187 by...
New project to train dogs to detect bowel cancer is officially underway
PetsRadar· 5 days ago“Prostate cancer has been a focus in the clinic. Diagnosis in the UK usually starts with a blood...
Nicotinell buy to give big boost to Dr Reddy's consumer healthcare play
The Week· 5 days agoDr Reddy's Laboratories has taken a big step in its ambitions to scale up its over-the-counter (OTC)...
Dr. Reddy’s to acquire Haleon’s global portfolio of consumer healthcare brands in Nicotine...
Financial Express· 6 days agoDr. Reddy’s Laboratories Ltd. on Wednesday announced that it is acquiring Haleon’s global portfolio...
Pharma M&A: The top high value deals in 2023
Pharmaceutical Technology· 6 days agoFrom Pfizer’s Seagen acquisition to Sanofi’s deal with Provention Bio, Pharmaceutical Technology lists the highest value pharma mergers and acquisitions...
